Status:
COMPLETED
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Advanced Hormone Sensitive Prostate Cancer
Eligibility:
MALE
Brief Summary
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional...
Eligibility Criteria
Inclusion
- Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer
Exclusion
- Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded
- Planned intermittent or short-term (\< 12 months) degarelix treatment
- Planned addition of, or switch to another form of androgen deprivation therapy during the study
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 4 2017
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT02229253
Start Date
September 1 2014
End Date
October 4 2017
Last Update
November 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Groene Hart Ziekenhuis (there may be other sites in this country)
Gouda, Netherlands